GlassScriptPhysician profile
Philip L Levin
NPI 1619051877
$748.48
in general payments reported to CMS, 2019-2025
15 companies · $213 in 2025
The $213 reported for 2025 was more than what 80% of Emergency Medical Services providers received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.35 · 2020: $146 · 2022: $156 · 2023: $137 · 2024: $33.04 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $175.29 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.87 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $120.38 | 2020 | |
| Lilly USA, LLC | $52.89 | 2019-2020 | |
| Abbott Laboratories | $48.93 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $35.01 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Instrumentation Laboratory Company | $25.00 | 2019 | |
| Bioventus LLC | $24.54 | 2023 | Durolane |
| Amgen INC. | $23.09 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.94 | 2023 | |
| Ucb, INC. | $20.96 | 2023 | Briviact |
| Pfizer INC. | $16.46 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.23 | 2022 | |
| Sumitomo Pharma America, INC. | $15.21 | 2025 | Gemtesa |
| Abbvie INC. | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.